Phospho-CBX3 (S93) Antibody

What is CBX3 and why is phosphorylation at S93 significant?

CBX3, also known as Heterochromatin Protein 1 gamma (HP1γ), is a chromobox family protein that plays crucial roles in heterochromatin formation and transcriptional silencing. This protein recognizes and binds histone H3 tails methylated at 'Lys-9', leading to epigenetic repression . The phosphorylation at Serine 93 is a post-translational modification that regulates CBX3's functional activity, particularly during cellular processes like DNA damage response and cell cycle progression . This specific phosphorylation event affects the protein's interaction with chromatin and other nuclear proteins, making it a key regulatory point in CBX3-mediated functions .

What cellular localization pattern should I expect when using Phospho-CBX3 (S93) antibody?

Phospho-CBX3 primarily localizes to the nucleus, as CBX3 is a nuclear protein associated with chromatin regulation. Within the nucleus, CBX3 associates predominantly with euchromatin and is largely excluded from constitutive heterochromatin . During mitosis, CBX3 may also associate with microtubules and mitotic poles . When performing immunofluorescence or immunohistochemistry, researchers should expect nuclear staining patterns, with possible variations depending on cell cycle stage and experimental conditions. Validation of specificity can be performed using knockout cell lines to confirm staining patterns.

How does CBX3 function differ from other HP1 family proteins?

CBX3 (HP1γ) is one of three mammalian HP1 homologs (α, β, and γ), each with distinct functions despite structural similarities. Unlike HP1α and HP1β that primarily associate with constitutive heterochromatin, CBX3/HP1γ is found in both euchromatic and heterochromatic regions. CBX3 contributes to the association of heterochromatin with the inner nuclear membrane through interaction with lamin B receptor (LBR) and is involved in the formation of functional kinetochore through interaction with MIS12 complex proteins . Additionally, CBX3 is recruited to sites of ultraviolet-induced DNA damage and double-strand breaks, suggesting a role in DNA repair mechanisms that may be distinct from other HP1 proteins .

What are the most established roles of CBX3 in epigenetic regulation?

CBX3 plays fundamental roles in chromatin organization and epigenetic regulation through several mechanisms. It recognizes and binds histone H3 tails methylated at 'Lys-9', leading to epigenetic repression and heterochromatin maintenance . CBX3 contributes to transcriptional silencing by recruiting various repressive complexes to chromatin. At the nuclear envelope, CBX3 helps tether heterochromatin to the nuclear periphery through interactions with the lamin B receptor at the inner nuclear membrane . Recent research has also implicated CBX3 in regulating genes related to cell cycle, mismatch repair, and immune-related pathways . These diverse functions position CBX3 as a multifaceted regulator of nuclear architecture and gene expression.

What are the optimal dilutions for different applications of Phospho-CBX3 (S93) Antibody?

The optimal dilutions for Phospho-CBX3 (S93) Antibody vary by application and should be determined empirically for each experimental setup. Based on manufacturer recommendations:

For Western blotting, start with a 1:1000 dilution and adjust based on signal strength and background levels . For immunohistochemistry applications, begin with 1:100 dilution for paraffin-embedded sections . When performing immunofluorescence, a starting dilution of 1:100 is recommended with optimization based on signal-to-noise ratio . Validation using positive and negative controls is essential for determining optimal conditions in your specific experimental system.

What controls should be included when working with Phospho-CBX3 (S93) Antibody?

Proper controls are essential for reliable interpretation of results with Phospho-CBX3 (S93) Antibody:

• Positive Control: Use cell lines or tissues known to express phosphorylated CBX3, such as HeLa, MCF-7, 293T, A549, or NCI-H460 cells .

• Negative Control: Include CBX3 knockout cells or tissues where available. Alternatively, use secondary antibody-only controls to assess non-specific binding .

• Phosphatase Treatment Control: Treat a portion of your samples with lambda phosphatase to demonstrate that the signal is specifically due to phosphorylation.

• Peptide Competition: Pre-incubate the antibody with the immunizing phosphopeptide to validate specificity.

• Total CBX3 Antibody: Run parallel samples with an antibody recognizing total CBX3 (regardless of phosphorylation) to assess the proportion of phosphorylated protein.

These controls will help distinguish specific phospho-CBX3 signal from background or non-specific staining, particularly important when examining subtle changes in phosphorylation status.

How can I validate the specificity of Phospho-CBX3 (S93) Antibody?

Validating the specificity of Phospho-CBX3 (S93) Antibody is crucial for reliable experimental results:

• Phosphatase Treatment: Split your samples and treat one portion with lambda phosphatase. The disappearance of signal in treated samples confirms phospho-specificity.

• Knockout Validation: Use CRISPR/Cas9-mediated CBX3 knockout cells as negative controls. Several commercial antibodies are now KO-validated, as indicated in product information .

• Peptide Competition: Pre-incubate the antibody with the immunizing phosphopeptide (derived from Human HP1γ around the phosphorylation site of S93). This should abolish specific binding .

• Phosphomimetic Mutants: Compare antibody recognition of wild-type CBX3, S93A (phospho-null), and S93D/E (phosphomimetic) mutants expressed in cells.

• Mass Spectrometry Correlation: For advanced validation, correlate antibody-based detection with mass spectrometry identification of the phosphorylation site.

These approaches provide complementary evidence for antibody specificity and should be selected based on the critical nature of your experiments.

What are effective sample preparation methods for detecting phosphorylated CBX3?

Proper sample preparation is critical for detecting phosphorylated CBX3:

• Phosphatase Inhibitors: Always include comprehensive phosphatase inhibitor cocktails in lysis buffers to prevent dephosphorylation during sample preparation (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate).

• Rapid Processing: Minimize the time between sample collection and protein extraction to prevent phosphorylation changes.

• Lysis Buffer Composition: Use RIPA or NP-40 based buffers with phosphatase inhibitors for general applications. For chromatin-bound proteins like CBX3, consider nuclear extraction protocols with high salt concentrations.

• Protein Preservation: Maintain samples at 4°C during processing and add protease inhibitors to prevent degradation.

• Fixation for IHC/IF: For tissue sections or cells, use phospho-preserving fixation methods (4% paraformaldehyde is often suitable) followed by appropriate antigen retrieval methods.

• Enrichment Strategies: For low-abundance phosphoproteins, consider phosphoprotein enrichment methods like phospho-specific immunoprecipitation prior to analysis.

These methods help maintain the phosphorylation status of CBX3 during sample preparation, ensuring accurate assessment of its modification state.

How is CBX3 phosphorylation implicated in cancer progression mechanisms?

CBX3 phosphorylation plays significant roles in cancer progression through multiple mechanisms:

• Transcriptional Reprogramming: Phosphorylated CBX3 modulates expression of genes involved in cell cycle regulation, DNA repair, and immune response pathways . In gastric cancer, CBX3 upregulation promotes malignant phenotypes through these mechanisms.

• Cell Cycle Regulation: CBX3 regulates genes related to the cell cycle, and its phosphorylation status may influence cell proliferation capacity . Knockdown of CBX3 in gastric cancer cells significantly inhibited the malignant phenotype, suggesting its phosphorylation may be crucial for maintaining cancer cell growth.

• Immune Environment Modulation: CBX3 expression inversely correlates with tumor-infiltrating lymphocytes (TILs) and affects expression of immune checkpoint genes including PDCD1, PDCD1LG2, CD274, and CTLA4 . The phosphorylation status may regulate these interactions, influencing tumor immune evasion.

• Therapeutic Response Prediction: High CBX3 expression correlates with chemotherapy sensitivity in gastric cancer, particularly to 5-fluorouracil (5-FU) . This suggests phosphorylated CBX3 may serve as a biomarker for predicting treatment response.

Understanding the specific role of S93 phosphorylation in these processes represents a frontier in cancer research that may yield new diagnostic and therapeutic approaches.

What is the relationship between CBX3 and tumor immune microenvironment?

CBX3 significantly influences the tumor immune microenvironment through several mechanisms:

• Negative Correlation with Immune Cell Infiltration: In gastric cancer, CBX3 expression negatively correlates with the abundance of tumor-infiltrating lymphocytes, including B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells . This suggests CBX3 may create an immunosuppressive microenvironment.

• Regulation of Immune Checkpoint Molecules: CBX3 expression is closely related to immune checkpoint genes, including PDCD1 (PD-1), PDCD1LG2 (PD-L2), CD274 (PD-L1), and CTLA4 . These molecules are critical for cancer immune evasion and targets for immunotherapy.

• Interferon Signaling Modulation: CBX3 represses genes significantly related to the interferon (IFN) signaling pathway, which is critical for both innate and adaptive immunity . Both IFN-γ and type I interferons play crucial roles in anticancer immunity and immunotherapeutic effects.

• Microsatellite Instability Association: Higher CBX3 expression correlates with increased microsatellite instability-high (MSI-H) status in gastric cancer (22.9% in high expression vs. 12.4% in low expression groups) . MSI status is a predictor of immunotherapy response.

These findings position CBX3 as a potential regulator of tumor-immune interactions and suggest its potential as a biomarker for immunotherapy response prediction.

How does CBX3 expression correlate with response to immunotherapy?

CBX3 expression shows significant correlation with immunotherapy response:

• Inverse Correlation with Immunotherapy Response: Analysis of anti-PD-1 immunotherapy datasets reveals that CBX3 expression in responder groups is significantly lower than in non-responder groups . This suggests that lower CBX3 levels may predict better outcomes for immune checkpoint blockade therapy.

• Immune Checkpoint Expression Regulation: CBX3 affects the expression of key immune checkpoint molecules including PDCD1 (PD-1) and PDCD1LG2 (PD-L2), which are directly related to immunotherapy efficacy .

• Tumor Mutation Burden (TMB) Association: CBX3 expression positively correlates with neoantigen count and tumor mutation burden, which are established predictors of immunotherapy response . This creates a complex relationship where high CBX3 may indicate higher TMB (favorable for immunotherapy) but also immunosuppression (unfavorable).

• MSI Status Influence: High CBX3 expression correlates with higher rates of microsatellite instability-high (MSI-H) status, which typically responds better to immunotherapy .

These findings suggest CBX3 could serve as a potential biomarker for predicting immunotherapy response, with its phosphorylation status possibly providing additional predictive value for precision medicine approaches.

What methods can be used to study the dynamic phosphorylation of CBX3 during cellular processes?

Studying dynamic phosphorylation of CBX3 requires specialized techniques:

• Live Cell Imaging: Use fluorescently-tagged CBX3 combined with phospho-specific antibodies and FRET techniques to monitor real-time phosphorylation changes during cell cycle progression or DNA damage response.

• Phosphoproteomics: Apply mass spectrometry-based approaches to quantify CBX3 phosphorylation at S93 and other sites across different cellular conditions or time points after stimulation.

• Phosphomimetic Mutants: Generate CBX3 constructs with S93A (phospho-null) and S93D/E (phosphomimetic) mutations to study functional consequences of constitutive or absent phosphorylation.

• Kinase Inhibitor Screening: Use selective kinase inhibitors to identify the kinases responsible for S93 phosphorylation under different cellular conditions.

• Chromatin Immunoprecipitation (ChIP): Compare genomic binding sites of phosphorylated versus non-phosphorylated CBX3 using phospho-specific antibodies coupled with sequencing (ChIP-seq).

• Proximity Ligation Assay (PLA): Detect interactions between phosphorylated CBX3 and its binding partners in situ within cells or tissues.

These methodologies provide complementary approaches to understand when, where, and how CBX3 phosphorylation occurs and its functional consequences in various biological contexts.

Why might Phospho-CBX3 (S93) Antibody show unexpected molecular weight bands in Western blot?

Unexpected bands in Western blots using Phospho-CBX3 (S93) Antibody can result from several factors:

• Post-translational Modifications: CBX3 undergoes multiple modifications beyond S93 phosphorylation, including other phosphorylation events, methylation, and ubiquitination, which can alter migration patterns.

• Isoform Expression: CBX3 has multiple transcript variants that may be expressed differently across tissues or cell types, potentially resulting in bands of different sizes .

• Proteolytic Degradation: Incomplete protease inhibition during sample preparation can result in degradation fragments that retain the phospho-epitope.

• Cross-reactivity: The antibody may recognize similar phospho-epitopes in related proteins, especially other HP1 family members with sequence homology.

• Mobility Shifts: Phosphorylation itself can cause significant mobility shifts in SDS-PAGE. The observed molecular weight of CBX3 (approximately 23 kDa) may differ from the calculated weight (20 kDa) due to these modifications .

• Non-specific Binding: Secondary antibody binding to endogenous immunoglobulins or insufficient blocking can cause non-specific bands.

To address these issues, include appropriate controls, optimize blocking conditions, and consider using knockout-validated antibodies that have been specifically tested for specificity.

How can background staining be reduced in IHC experiments with Phospho-CBX3 (S93) Antibody?

To reduce background staining in immunohistochemistry with Phospho-CBX3 (S93) Antibody:

• Optimize Antibody Dilution: Test a range of antibody dilutions (1:50-1:300 as recommended) to find the optimal concentration that maximizes specific signal while minimizing background .

• Blocking Optimization: Extend blocking time (1-2 hours) using 5-10% normal serum from the same species as the secondary antibody, plus 1% BSA and 0.1-0.3% Triton X-100 for permeabilization.

• Washing Protocol: Implement more stringent washing steps (4-5 washes of 5-10 minutes each) with TBS-T (0.1% Tween-20) after primary and secondary antibody incubations.

• Antigen Retrieval Refinement: Test different antigen retrieval methods (citrate buffer pH 6.0 vs. EDTA buffer pH 9.0) and adjust retrieval time to optimize epitope accessibility without increasing non-specific binding.

• Secondary Antibody Selection: Use highly cross-adsorbed secondary antibodies specific to the primary antibody host species to minimize cross-reactivity.

• Endogenous Peroxidase Quenching: For HRP-based detection systems, thoroughly quench endogenous peroxidase activity using 0.3-3% hydrogen peroxide in methanol for 10-30 minutes.

• Tissue-Specific Considerations: For tissues with high endogenous biotin, implement avidin-biotin blocking steps if using biotin-based detection systems.

Systematic optimization of these parameters will help achieve clean, specific staining with minimal background interference.

What factors might influence phosphorylation levels of CBX3 in experimental samples?

Several factors can significantly affect CBX3 phosphorylation levels in experimental samples:

• Cell Cycle Stage: Phosphorylation of CBX3 often varies throughout the cell cycle, with potential increases during mitosis. Synchronize cells or use cell cycle markers in your analysis to account for this variation.

• Growth Factor Stimulation: Serum starvation followed by serum/growth factor reintroduction can trigger signaling cascades that alter CBX3 phosphorylation. Control growth factor exposure time and concentration in your experiments.

• Cellular Stress: DNA damage, oxidative stress, and hypoxia can induce changes in CBX3 phosphorylation. Document and standardize stress conditions across experimental replicates.

• Sample Preparation: Phosphatase activity during sample preparation can rapidly dephosphorylate CBX3. Always use fresh, comprehensive phosphatase inhibitor cocktails in all buffers.

• Drug Treatments: Kinase inhibitors or activators, even those not directly targeting CBX3-related pathways, may indirectly affect its phosphorylation state through signaling crosstalk.

• Cell Density and Contact Inhibition: Confluency levels can affect kinase activity and consequently CBX3 phosphorylation. Standardize cell density across experiments.

• Fixation Protocols: For IHC/IF, fixation methods and duration can affect phospho-epitope preservation. Optimize fixation protocols specifically for phosphorylated proteins.

Understanding and controlling these variables is essential for generating reproducible data regarding CBX3 phosphorylation status.

How can researchers differentiate between phosphorylated and non-phosphorylated forms of CBX3?

Differentiating between phosphorylated and non-phosphorylated CBX3 requires specific techniques:

• Parallel Antibody Approach: Use both phospho-specific (S93) and total CBX3 antibodies on parallel samples to compare signals and calculate the proportion of phosphorylated protein.

• Phosphatase Treatment: Divide samples into treated and untreated groups. Lambda phosphatase treatment should eliminate the phospho-specific signal while total CBX3 signal remains.

• Phos-tag™ SDS-PAGE: This specialized gel system retards the migration of phosphorylated proteins, creating a visible mobility shift compared to non-phosphorylated forms without requiring phospho-specific antibodies.

• 2D Gel Electrophoresis: Combines isoelectric focusing with SDS-PAGE to separate proteins based on both charge (affected by phosphorylation) and size, allowing visualization of different phospho-states.

• Mass Spectrometry: Quantitative phosphoproteomics can precisely measure the stoichiometry of phosphorylation at S93 and identify other modification sites.

• Immunoprecipitation Strategy: Perform sequential immunoprecipitation with phospho-specific antibody followed by total CBX3 antibody to determine the fraction of phosphorylated protein.

• Proximity Ligation Assay: Use pairs of antibodies (anti-CBX3 and anti-phospho-S93) to detect and quantify co-localization of the total protein and the phosphorylated form in situ.

These complementary approaches provide multiple lines of evidence to accurately determine the phosphorylation status of CBX3 in your experimental system.

How does CBX3 expression correlate with chemotherapy sensitivity in cancer?

CBX3 expression demonstrates significant correlations with chemotherapy response, particularly in gastric cancer:

• 5-Fluorouracil (5-FU) Sensitivity: High CBX3 expression increases sensitivity to 5-FU chemotherapy, as demonstrated by significantly different estimated IC50 values between high and low CBX3 expression groups . Among patients treated with 5-FU, the high CBX3 expression group showed longer survival compared to the low expression group.

• Survival Advantage Reversal: Interestingly, while CBX3 generally promotes malignant phenotypes, high CBX3 expression confers a survival advantage specifically in patients who undergo chemotherapy, especially in stage III gastric cancer patients . This represents a paradoxical relationship where a marker of aggressive disease also predicts better treatment response.

• Treatment-Dependent Prognostic Value: In patients not treated with chemotherapy, there was a significant survival benefit in the low CBX3 group compared to the high CBX3 group, demonstrating that CBX3's prognostic value is treatment-dependent .

• Predictive Biomarker Potential: These findings suggest CBX3 could serve as a predictive biomarker for selecting patients who might particularly benefit from chemotherapy, especially 5-FU-based regimens.

This relationship highlights the complex role of CBX3 in cancer biology and treatment response, suggesting its potential utility in personalized treatment decisions.

What is the relationship between CBX3 and microsatellite instability in cancer?

CBX3 shows important associations with microsatellite instability (MSI) in cancer:

• Positive Correlation with MSI-H Status: In gastric cancer, the proportion of microsatellite instability-high (MSI-H) cases in the CBX3 high expression group (22.9%) was significantly higher than in the low expression group (12.4%) . This suggests a potential regulatory relationship between CBX3 and DNA mismatch repair mechanisms.

• Mismatch Repair Pathway Regulation: RNA-seq analysis revealed that CBX3 regulates genes related to mismatch repair pathways . This functional relationship may explain the correlation between CBX3 expression and MSI status.

• Immunotherapy Response Prediction: The association between CBX3 and MSI-H status has implications for immunotherapy response, as MSI-H tumors typically show better responses to immune checkpoint inhibitors.

• Complex Relationship with Tumor Mutation Burden: CBX3 expression positively correlates with tumor mutation burden (TMB) and neoantigen count , both of which are often elevated in MSI-H tumors and contribute to immunotherapy response.

These findings suggest CBX3 may be involved in the biological processes that determine MSI status, with important implications for both understanding cancer biology and predicting treatment responses, particularly to immunotherapy.

Can Phospho-CBX3 (S93) serve as a biomarker for cancer diagnosis or prognosis?

Phospho-CBX3 (S93) shows promising potential as a cancer biomarker:

• Expression in Cancer Tissues: CBX3 is upregulated in human gastric cancer tissues compared to normal tissues, and its expression levels correlate with adverse clinical signs . The specific phosphorylation at S93 could provide even more precise diagnostic information.

• Prognostic Value: CBX3 expression levels correlate with patient survival, though this relationship is complex and depends on treatment status . In untreated patients, high CBX3 expression predicts worse outcomes, suggesting its value as a prognostic marker.

• Treatment Response Prediction: High CBX3 expression correlates with better responses to chemotherapy (particularly 5-FU) and potentially to immunotherapy . Phosphorylation status may provide additional resolution in predicting which patients will respond to specific treatments.

• Association with Molecular Features: CBX3 correlates with important molecular features including microsatellite instability and tumor mutation burden , which are established biomarkers themselves. Phospho-CBX3 could complement these markers in a panel approach.

• Functional Relevance: Since CBX3 phosphorylation affects its function in chromatin regulation and gene expression, measuring the phosphorylated form may provide more direct insight into active disease processes than total protein levels.

While further clinical validation is needed, these findings suggest that phospho-CBX3 (S93) could serve as a valuable biomarker for cancer diagnosis, prognosis, and treatment selection, particularly in gastric cancer.

What emerging therapeutic strategies target CBX3 or its regulatory pathways?

Several promising therapeutic approaches targeting CBX3 are emerging:

• Small Molecule Inhibitors: Development of compounds that specifically disrupt CBX3's chromodomain binding to methylated histones, potentially reversing its epigenetic repressive effects in cancer.

• Targeting Phosphorylation: Identification of kinases responsible for S93 phosphorylation offers potential for targeted inhibition to modulate CBX3 function in specific contexts.

• Combination with Immunotherapy: Given CBX3's relationship with immune checkpoint molecules and the tumor immune microenvironment , combining CBX3 inhibition with immune checkpoint blockade could enhance immunotherapy efficacy.

• Synthetic Lethality Approaches: Exploiting CBX3's role in DNA repair pathways to create synthetic lethal interactions with other DNA damage response inhibitors, particularly in cancers with high replication stress.

• Epigenetic Combination Therapy: Targeting CBX3 alongside other epigenetic regulators like histone deacetylases (HDACs) or DNA methyltransferases to achieve synergistic reprogramming of cancer cell gene expression.

• Biomarker-Guided Chemotherapy: Using CBX3 expression as a biomarker to select patients who would benefit from specific chemotherapy regimens, particularly 5-FU-based treatments in gastric cancer .